1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CACancer J Clin. 2018;68(6):394-424.

[CrossRef]
PMid:30207593

2. American Cancer Society, Cancer Facts & Figures 2018. http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Pristupljeno: mart 2019.

3. Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland 2013/2014;10. Ausgabe,Berlin 2015.

4. https://eliph.klinikum.uniheidelberg.de/texte_s/651/bronchialkarzinom.Pristupljeno:mart 2017.

5. Travis WD. Reporting lung cancer pathologal specimens. Impact of the anticipated 7th Edition TNM Classification based on recommendation of the IASLC Staging Committee. Histopathology. 2009; 54(1): 3-11.

[CrossRef]
PMid:19187176

6. Helmut H. Popper. Progression and metastasis of lung cancer. Cancer Metastais Rev. 2016; 35: 75-79.

[CrossRef]
PMid:27018053 PMCid:PMC4821869

7. Matias Riihimaki, Hauke Thomsen, Kristina Sundquist, Jan Sundquist, Kari Hemminiki. Clinicall landscape of cancer metastases. Cancer Med. 2018; 7(11): 5534-5542.

[CrossRef]
PMid:30328287 PMCid:PMC6246954

8. Tamura T., Kurishima K., Nakazawa K., Kagohashi K., Ishikawa H., Satoh H. Specific organ metastases and survival in metastatic non-cmall-cell lung cancer. Molecular and Clinical Oncology. 2015; 3: 217-221.

[CrossRef]
PMid:25469298 PMCid:PMC4251107

9. William D. Travis, MD, Elisabeth Brambilla, MD, Masayuki Noguchi, MD, Andrew G, Nicholson, MD, Kim R. Geisinger, MD, Yasushi Yatabe, et al. International Association for the Study of Lung Cancer, J Thorac Oncol. 2011; 6(2): 244-285.

10. Mollberg NM, Bennette C et al. Lymphovascular invasion as a prognostic indicator in stage I nonsmall cell lung cancer: a systemic review and metaanalysis. Ann Thorac Surg. 2014; 97(3): 965-971.

[CrossRef]
PMid:24424014

11. Sung SY, Kwak YK, Lee SW, Jo IY, Park JK, Kim KS, Lee KY, Kim YS. Lymphovascular Invasion Increases the Risk of Nodal and Distant Recurrence in Node-Negative Stage I-IIA Non-Small-Cell Lung Cancer. Oncology 2018; 30:1-7.

[CrossRef]
PMid:29847825

12. Okiror L, Harling L, Toufektzian L, King J, Routledge T, Harrison-Phipps K. Prognostic factors including lymphovascular invasion on survival for resected non-small cell lung cancer, J Thorac Cardiovasc Surg. 2018; 156(2): 785-793.

[CrossRef]
PMid:29754785

13. W. D.Travis, MD, E. Brambilla, MD, A. G. Nicholson, MD et al. The 2015 World Healt OrganizationClassification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J. Thorac Oncol. 2015; 10: 1243-1260.

14. Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015; 10(7): 990-1003.

[CrossRef]
PMid:26134221

15. Wang S, Zhang B, Qian J, Qiao R, Xu J, Zhang L, Zhao Y et al. Proposal on incorporating lymphovascular invasion as a T-descriptor for stage Ilung cancer. Lung Cancer 2018; 2018: 245-252.

[CrossRef]
PMid:30429028

16. Park C, In Lee IJ, Jang SH, Lee JW. Factors affecting tumor recurrence after curative surgery for NSCLC: impacts of lymphovascular invasion on early tumor recurrence. J Thorac Dis. 2014; 6(10); 1420-1428.